Neurocrine Biosciences (NASDAQ: NBIX) reported weaker-than-expected Q4 results, missing both earnings and revenue estimates due to higher expenses. Despite the miss, shares of …
This article was originally published on TipRanks.com Neurocrine (NBIX) is an American biopharmaceutical company based in California.
Neurocine Biosciences (NBIX) stock dropped about 14% Wednesday after news that its clinical trial for Ingrezza T-Force GOLD, for the treatment of Tourrette …
BlackBerry Ltd (NASDAQ:BBRY) and Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are rattling the market today with massive wins in their favor that have investors putting …
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) investors have a smile on their faces this morning, following the news that the FDA has approved INGREZZA (valbenazine) …
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares are on a 7% rise after the company revealed yesterday the FDA has cancelled its prior-scheduled Advisory Committee …